

Uri Lopatin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6962024/publications.pdf>

Version: 2024-02-01

24
papers

2,034
citations

394421

19
h-index

610901

24
g-index

25
all docs

25
docs citations

25
times ranked

2571
citing authors

#	ARTICLE	IF	CITATIONS
1	Severe Community-Onset Pneumonia in Healthy Adults Caused by Methicillin-Resistant <i>Staphylococcus aureus</i> Carrying the Panton-Valentine Leukocidin Genes. <i>Clinical Infectious Diseases</i> , 2005, 40, 100-107.	5.8	657
2	Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. <i>Lancet, The</i> , 2010, 376, 1467-1475.	13.7	313
3	Increases in circulating and lymphoid tissue interleukin-10 in autoimmune lymphoproliferative syndrome are associated with disease expression. <i>Blood</i> , 2001, 97, 3161-3170.	1.4	112
4	Interactions among dendritic cells, macrophages, and epithelial cells in the gut: implications for immune tolerance. <i>Current Opinion in Immunology</i> , 2008, 20, 669-675.	5.5	97
5	Effect of IL28B Genotype on Early Viral Kinetics During Interferon-Free Treatment of Patients With Chronic Hepatitis C. <i>Gastroenterology</i> , 2012, 142, 790-795.	1.3	91
6	Transcriptomic analysis of the woodchuck model of chronic hepatitis B. <i>Hepatology</i> , 2012, 56, 820-830.	7.3	88
7	Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 152-166.	8.1	85
8	Reduction of HBV replication prolongs the early immunological response to IFN α therapy. <i>Journal of Hepatology</i> , 2014, 60, 54-61.	3.7	75
9	Actinomyces in Chronic Granulomatous Disease: An Emerging and Unanticipated Pathogen. <i>Clinical Infectious Diseases</i> , 2009, 49, 1703-1710.	5.8	74
10	Reactivation of Hepatitis B With Reappearance of Hepatitis B Surface Antigen After Chemotherapy and Immunosuppression. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 1130-1137.	4.4	62
11	Drugs in the Pipeline for HBV. <i>Clinics in Liver Disease</i> , 2019, 23, 535-555.	2.1	55
12	Safety, Pharmacokinetics and Pharmacodynamics of Gs-9620, An Oral Toll-Like Receptor 7 Agonist. <i>Antiviral Therapy</i> , 2013, 18, 409-418.	1.0	53
13	Guidance for Design and Endpoints of Clinical Trials in Chronic Hepatitis B Report From the 2019 EASL AASLD HBV Treatment Endpoints Conference. <i>Hepatology</i> , 2020, 71, 1070-1092.	7.3	52
14	Targeting Hepatitis B Virus-Infected Cells with a T-Cell Receptor-Like Antibody. <i>Journal of Virology</i> , 2011, 85, 1935-1942.	3.4	48
15	Hepatitis B virus Core protein nuclear interactome identifies SRSF10 as a host RNA-binding protein restricting HBV RNA production. <i>PLoS Pathogens</i> , 2020, 16, e1008593.	4.7	28
16	LBO-06-Interim safety and efficacy results of the ABI-H0731 phase 2a program exploring the combination of ABI-H0731 with Nuc therapy in treatment-naïve and treatment-suppressed chronic hepatitis B patients. <i>Journal of Hepatology</i> , 2019, 70, e130.	3.7	23
17	HBsAg loss in patients treated with peginterferon alfa-2a and adefovir is associated with SLC16A9 gene variation and lower plasma carnitine levels. <i>Journal of Hepatology</i> , 2014, 61, 730-737.	3.7	22
18	Lymphotoxin Alpha-Deficient Mice Clear Persistent Rotavirus Infection after Local Generation of Mucosal IgA. <i>Journal of Virology</i> , 2013, 87, 524-530.	3.4	21

#	ARTICLE	IF	CITATIONS
19	Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection. <i>Journal of Hepatology</i> , 2022, 77, 1265-1275.	3.7	21
20	Characterization of a <i>Mycobacterium smegmatis</i> Mutant That Is Simultaneously Resistant to d-Cycloserine and Vancomycin. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 1701-1704.	3.2	20
21	Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection. <i>Journal of Hepatology</i> , 2022, 77, 642-652.	3.7	17
22	Viral minority variants in the core promoter and precore region identified by deep sequencing are associated with response to peginterferon and adefovir in HBeAg negative chronic hepatitis B patients. <i>Antiviral Research</i> , 2017, 145, 87-95.	4.1	12
23	LBP-12-Phase 1a Study of the Safety, Tolerability and Pharmacokinetics of ABI-H, a Novel Second-Generation HBV Core Inhibitor, in Healthy Volunteers. <i>Journal of Hepatology</i> , 2019, 70, e146-e147.	3.7	4
24	US immigration order strikes against biotech. <i>Nature Biotechnology</i> , 2017, 35, 204-206.	17.5	2